Answers are grounded in this paper and cite their sources.
The concept underlying much of cancer therapy is that patients with specific types and stages of cancer should be treated according to standardized, predetermined protocols. However, recent advances in drug development, pharmacogenomics, and the molecular characterization of tumors — including genomewide RNA expression, DNA copy-number and sequence analyses, and microRNA and proteomic profiling — have the potential to allow individualized selection of treatment as determined by the characteristics of the patient and the tumor.In principle, targeted therapies attack cancer-cell–specific attributes that are essential for growth or survival (“oncogene addiction”) and avoid the potentially severe side effects of conventional cytotoxic . . .
No takes yet. Share an insight, caveat, or question.
Adi F. Gazdar (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: